AUBURNDALE, Mass.--(BUSINESS WIRE)--Vascular Nanotransfer Technologies (“VNT”) (www.vnanotech.com), an emerging medical technology company, announced today that large animal model in vivo tests of its paclitaxel nanocarrier-based Drug Coated Balloon (“DCB”) achieved tissue levels comparable to devices with proven clinical efficacy.
